Key Takeaways Masimo reported a strong Q3 2025, driven by demand for non-invasive monitoring and a solid product portfolio.MASI gains FDA clearance to expand O3 oximetry use and renews a long-term monitoring tie-up with Philips.MASI remains exposed to risks from heavy dependence on SET platforms and reimbursement pressure from insurers.Masimo Corporation (MASI) is well-poised for growth in the coming quarters, courtesy of its strong underlying demand for innovative technology and research and development (R ...